Abstract
Background The European Centre for Disease Prevention and Control (ECDC) provides listings of medical conditions conferring high- or moderate-risk for severe COVID-19. In addition, individual European countries developed their own risk classifications for severe COVID-19 to select individuals recommended for annual COVID-19 vaccination. We assessed the discordance between the European and respective national medical risk classifications in assigning children and adults to risk groups for developing severe COVID-19 in populations of the Netherlands and Norway.
Methods This multi-country, healthcare data-linkage study covered 17.4 million inhabitants of the Netherlands and 5.6 million inhabitants of Norway by 1 January 2020. Medical conditions were defined based on ICD-10 hospital discharge codes in the European and Dutch classifications, and on ICD-10 and ICPC-2 primary care codes in the Norwegian classification. Subjects were classified as high-, moderate-, or low-risk. Discordance was calculated as the proportion of the population with a different risk status in the respective national compared to the European classification.
Findings The overall discordance between European and national risk classification was 12.0% in the Dutch and 13.8% in the Norwegian population. The European classification assigns more individuals to high-risk (9.0% and 9.2% of the Dutch and Norwegian populations, respectively) than the national classifications (1.5% and 3.0%, respectively). National classifications define more individuals as moderate-risk (11.3% and 12.7%, respectively) than the European classification (1.0% and 1.3%, respectively). Classification discordances most frequently involved subjects with cardiovascular disease, lung disease, and diabetes mellitus.
Interpretation The European classification defines a substantially larger percentage of the population as high-risk for severe COVID-19 than the national classifications. This may have implications for post-pandemic vaccination programs. Further research should assess to what extent the medical conditions responsible for the classification discordances determine the risk of developing severe COVID-19.
Funding ZonMw, EU, FCT, Norwegian Research Council’s COVID-19 Emergency Call, iAPOGEE.
Evidence before this study We searched PubMed for English-language articles published from 1 January 2020 to 1 July 2024, using the search terms ((((“COVID-19“[Title] OR “SARS-CoV-2“[Title]) AND (“sever*“[Title] OR “hospital*“[Title] OR “death“[Title] OR “decease*“[Title]) AND (“chronic condition*“[Title/Abstract] OR “comorbidit*“[Title/Abstract]) AND (“guideline“[Title] OR “classification“[Title] OR “system“[Title]) AND 2020/01/01:2024/07/01[Date - Create]) NOT “clinical trial“[Publication Type]) NOT “case reports“[Publication Type]). This search identified 64 studies, but none of them assessed the impact of different medical risk classifications for severe COVID-19 or compared them across countries or to the European classification.
Added value of this study To the best of our knowledge, this is the first study that compared the impact of European and national medical risk classifications for severe COVID-19 by assigning the populations of the Netherlands and Norway to medical risk groups using national healthcare registries. We demonstrated important discrepancies between the European and respective national schemes in classifying high- and moderate-risk individuals in both countries. The chronic conditions responsible for the classification discordances were lung disease, cardiovascular disease, neurological disorders, diabetes mellitus, cancer, and hypertension.
Implications of all the available evidence Our comparative analysis suggests that the choice between the European and national classifications may have important consequences for public health interventions such as vaccination campaigns. The variability in risk assignment based on chronic medical conditions underscores the absence of an international uniform approach. More research is needed to determine the extent to which each chronic medical condition impacts COVID-19 severity in the post-pandemic period, facilitating the refinement of risk classifications and supporting targeted public health interventions.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
GR, IW, AdB, and OB were supported by the ZonMw project (10430362220002). GR was supported by Fundacao para a Ciencia e a Tecnologia project 2022.01448.PTDC, DOI 10.54499/2022.01448.PTDC. GR, IW, AL, and PB were supported by the VERDI project (101045989), funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the Health and Digital Executive Agency. Neither the European Union nor the granting authority can be held responsible for them. IW was supported by the scholarship program iAPOGEE (International Alliance for PharmacoGenetic Epidemiology Excellence) at the University of Oslo, Norway. Data acquisition of the Norwegian data in this study was funded by HNs EU-COVID-19 project, funded by the Norwegian Research Councils COVID-19 Emergency Call (project no. 31270).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
